Efficacy and Safety of Janagliflozin as Add-on Therapy to Metformin in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Alone: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial.

Janagliflozin 25 mg or 50 mg once-daily added to metformin therapy significantly improved glycemic control, reduced body weight and SBP, improved HDL-C and insulin sensitivity, and was generally well-tolerated by Chinese T2DM patients who had poor glycemic control with metformin monotherapy. This article is protected by copyright. All rights reserved.